Advertisement

Insulin Resistance

Definition and Epidemiology in Normal Women and Polycystic Ovary Syndrome Women
  • Renato Pasquali
  • Alessandra Gambineri
Chapter
  • 1.1k Downloads
Part of the Contemporary Endocrinology book series (COE)

Abstract

Insulin resistance and hyperinsulinemia are key features of women with polycystic ovary syndrome (PCOS), particularly in the presence of obesity. This has important effects in the pathophysiology of this disorder and contributes largely to its changing aspects throughout the lifespan. Insulin excess does in fact have a direct responsibility in favoring androgen excess and oligo-anovulation in PCOS. On the other hand, insulin resistance represents the main pathophysiological event leading to the development of the metabolic syndrome, which affects almost 50% of women with PCOS.

Insulin resistance and the metabolic syndrome probably represent different entities and, therefore, should not be used as a synonym. Although there are no epidemiological data, it appears that the incidence of insulin resistance in PCOS exceeds the prevalance expected in the general population. On the other hand, although prevalence largely depends on the method used, insulin resistance in PCOS appears to be even higher in the presence of obesity, particularly the abdominal phenotype. Insulin resistance may be found, however, even in some normal-weight women with PCOS. Notably, the larger the number of criteria used to define the metabolic syndrome, the higher the probability that affected women are insulin resistant.

Recognition of these abnormalities in PCOS women may be of relevance for both treatment and preventive strategies. It is in fact well defined that PCOS itself, and even more so in the presence of obesity and a positive family history, may increase individual susceptibility to an early development of T2DM.

Key Words

PCOS insulin resistance glucose intolerance type 2 DM metabolic syndrome 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Ehrmann DA. Polycystic ovary syndrome. N Engl J Med 2005;352:1223–1236.CrossRefPubMedGoogle Scholar
  2. 2.
    The Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod 2004;19:41–47.CrossRefGoogle Scholar
  3. 3.
    Legro RS. The genetics of obesity: lessons for polycystic ovary syndrome. Ann NY Acad Sci 2000; 900:193–202.PubMedCrossRefGoogle Scholar
  4. 4.
    Dunaif A. Insulin resistance and the polycystic ovary syndrome: mechanisms and implications for pathogenesis. Endocr Rev 1997;18:774–800.CrossRefPubMedGoogle Scholar
  5. 5.
    Poretsky L, Cataldo NA, Rosenwaks Z, Giudice LC. The insulin-related ovarian regulatory system in health and disease. Endocr Rev 1999;20:535–582.CrossRefPubMedGoogle Scholar
  6. 6.
    Gambineri A, Pelusi C, Vicennati, Pagotto U, Pasquali R. Obesity and the polycystic ovary syndrome. Int J Obes Relat Metab Dis 2002;26:883–896.CrossRefGoogle Scholar
  7. 7.
    Apridonidze T, Essah P, Iourno MJ, Nestler JE. Prevalence and characteristics of the metabolic syndrome in women with PCOS. J Clin Endocrinol Metab 2005;90:1929–1935.CrossRefPubMedGoogle Scholar
  8. 8.
    Beck-Nielsen H, Alford F, Hother-Nielsen O. Insulin resistance in glucose disposal and production in man with specific reference to metabolic syndrome and type 2 diabetes. In: Kumar S, O’Railly S, eds. Inb Insulin Resistance. New York: John Wiley and Sons Ltd., 2000, pp. 155–178.Google Scholar
  9. 9.
    Radziuk J. Insulin sensitivity and its measurement: structural commonalities among the methods. J Clin Endocrinol Metab 2000;85:4426–4433.CrossRefPubMedGoogle Scholar
  10. 10.
    Bergman RN, Finegood DT, Ader M. Assessment of insulin sensitivity in vivo. Endocr Rev 1985;6:45–86.CrossRefPubMedGoogle Scholar
  11. 11.
    Weber KM, Martin IK, Best JD, Alford FP, Boston RC. Alternative methods for minimal model analysis of intravenous glucose tolerance data. Am J Physiol 1989;256:E524–E535.PubMedGoogle Scholar
  12. 12.
    Mattews Dr, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Flomeostasis model assessment: insulin resistance and B-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985;28:412–419.CrossRefGoogle Scholar
  13. 13.
    Katz A, Nambi SS, Mater K, et al. Quantitative insulin sensitivity check index: a simple, accurate method for assessing insulin sensitivity in humans. J Clin Endocrinol Metab 2000;85:2402–2410.CrossRefPubMedGoogle Scholar
  14. 14.
    Dunaif A, Finegood DT. ß-cell dysfunction independent of obesity and glucose intolerance in the polycystic ovary syndrome. J Clin Endocrinol Metab 1996;81:942–947.CrossRefPubMedGoogle Scholar
  15. 15.
    Hrebicek J, Janout V, Malincikova J, Horakova D, Cizek L. Detection of insulin resistance by simple quantitative insulin sensitivity check index QUICKI for epidemiological assessment and prevention. J Clin Endocrinol Metab 2002;87:144–147.CrossRefPubMedGoogle Scholar
  16. 16.
    Reaven GM. The metabolic syndrome or the insulin resistance syndrome? Different names, different concepts, and different goals. Endocrinol Metab Clin N Am 2004;33:283–303.CrossRefGoogle Scholar
  17. 17.
    Carmina E, Lobo R. Use of fasting blood to assess the prevalence of insulin resistance in women with polycystic ovary syndrome. Fertil Steril 2004;82:661–665.CrossRefPubMedGoogle Scholar
  18. 18.
    Diamanti-Kandarakis E, Kouli C, Alexandraki K, Spina G. Failure of mathematical indices to accurately assess insulin resistance in lean, overweight, or obese women with polycystic ovary syndrome. J Clin Endocrinol Metab 2004;89:1273–1276.CrossRefPubMedGoogle Scholar
  19. 19.
    Ciampelli M, Leoni F, Cucinelli F, et al. Assessment of insulin sensitivity from measurements in the fasting state and during an oral glucose tolerance test in polycystic ovary syndrome and menopausal patients. J Clin Endocrinol Metab 2005;90:1389–1406.Google Scholar
  20. 20.
    Avignon A, Boegner C, Mariano-Goular D, Colette C, Monnier L. Assesment of insulin sensitivity from plasma insulin and glucose in the fasting or post oral glucose-load state. In J Obes Rel Metab Dis 1999;23:512–517.CrossRefGoogle Scholar
  21. 21.
    Mari A, Pacini G, Brazzale AR, Ahren B. Comparative evaluation of simple insulin sensitivity methods based on the oral glucose tolerance test. Diabetologia 2005;48:748–751.CrossRefPubMedGoogle Scholar
  22. 22.
    Yeni-Konshian H, Carantoni M, Abbasi F, Reaven GM. Relationship between several surrogate estimates of insulin resistance and quantification of insulin-mediated glucose disposal in 4090 healthy, nondiabetic volunteers. Diabetes Care 2000;23:171–175.CrossRefGoogle Scholar
  23. 23.
    Reaven GM. Insulin resistance in human disease. Diabetes 1988;37:1595–1607.CrossRefPubMedGoogle Scholar
  24. 24.
    Avogaro P, Crepaldi G, Enzi G, Tiengo A. Associazione di iperlipidemia, diabete mellito e obesità di medio grado. Acta Diabetol Lat 1967;4:36–41.CrossRefGoogle Scholar
  25. 25.
    International Diabetes Federation: the IDF worldwide definition of the metabolic syndrome. Available from http://www.cdc.gov/nchs/about/major/nhanes/nhanes/99-02.htm. Accessed 18 May 2005.Google Scholar
  26. 26.
    Wu FC, von Eckardstein A. Androgens and coronary artery disease. Endocr Rev 2003;24:183–217.CrossRefPubMedGoogle Scholar
  27. 27.
    Bjorntorp P, Rosmond R. The metabolic syndrome-a neuroendocrine disorder. Br J Nutr 2000;83:S49–S57.CrossRefPubMedGoogle Scholar
  28. 28.
    Executive Summary of the Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001;285:2486–2497.Google Scholar
  29. 29.
    Ford ES. Prevalence of the metabolic syndrome in US population. Ehdocrinol Metab Clin N Am 2004;33:333–350.CrossRefGoogle Scholar
  30. 30.
    Resnick HE. Strong Heart Study Investigators: metabolic syndrome in American Indians. Diabetes Care 2002;25:1246–1247.CrossRefPubMedGoogle Scholar
  31. 31.
    American College of Endocrinology Task Force on the Insulin Resistance Syndrome. American College of Endocrinology Position Statement on the Insulin Resistance Syndrome. Endocr Pract 2002;9:236–252.Google Scholar
  32. 32.
    Alberti K, Zimmet P. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus. Report of a WHO consultation. Diab Med 1998;15:539–553.CrossRefGoogle Scholar
  33. 33.
    World Heath Organization. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus. Geneva (Switzerland): Department of Noncommunicable Disease Surveillance; 1999.Google Scholar
  34. 34.
    Ford ES, Giles WH. A comparison of the prevalence of the metabolic syndrome using two proposed definitions. Diabetes Care 2003;26:575–581.CrossRefPubMedGoogle Scholar
  35. 35.
    Meigs JB, Wilson PW, Nathan DM, D’Agostino RB Sr. Williams K, Haffner SM. Prevalence and characteristics of the metabolic syndrome in the San Antonio Heart and Framingham Offspring Studies. Diabetes 2003;52:2160–2167.CrossRefPubMedGoogle Scholar
  36. 36.
    Cameron AJ, Shaw JE, Zimmet PZ. The metabolic syndrome: prevalence in worldwide populations. Endocrinol Metab Clin N Am 2004;33:351–375.CrossRefGoogle Scholar
  37. 37.
    Balkau B, Charles MA. Comment on the provisional report from the WHO consultation. European Group for the Study of Insulin Resistance (EGIR). Diab Med 1999;16:442–443.CrossRefGoogle Scholar
  38. 38.
    Gu D, Reynolds K, Wu X, Chem J, et al. Inter ASIA Collaborative Group. Prevalence of the metabolic syndrome and overweight among adults in China. Lancet 2005;365:1398–1405.CrossRefPubMedGoogle Scholar
  39. 39.
    Kahn R, Ferrranini E, Buse J, Stern M. The metabolic syndrome: time for a critical rappraisal. Joint statement from the American Diabetes Association and the European Association for the study of Diabetes. Diabetes Care 2005;28:2289–2304.CrossRefPubMedGoogle Scholar
  40. 40.
    Orio F Jr. Palomba S, Cascella T, et al. The increase of leukocytes as a new putative marker of low-grade chronic inflammation and early cardiovascular risk in polycystic ovary sindrome. J Clin Endocrinol Metab 2005;90:2–5.CrossRefPubMedGoogle Scholar
  41. 41.
    Cheal KL, Abbasi F, Lamendola C, McLaughlin T, Reaven GM, Ford ES. Relationship to insulin resistance of the adult treatment panel III diagnostic criteria for identification of the metabolic syndrome. Diabetes 2004;53:1195–1200.CrossRefPubMedGoogle Scholar
  42. 42.
    Greenfield MS, Doberne L, Kraemer F, Tobey T, Reaven GM. Assessment of insulin resistance with insulin suppression test and the euglycemic clam. Diabetes 1981;30:387–392.CrossRefPubMedGoogle Scholar
  43. 43.
    Azziz JR, Sanchez LA, Knochenhauer ES, et al. Androgen excess in women: experience with over 1000 consecutive patients. J Clin Endocrinol Metab 2004;89:453–462.CrossRefPubMedGoogle Scholar
  44. 44.
    Cibula D. Is insulin resistance an essential component of PCOS? Hum Reprod 2004;19:757–759.CrossRefPubMedGoogle Scholar
  45. 45.
    Ehrmann DA, Sturis J, Byrne MM, Karrison T, Rosenfield RL, Polonsky KS. Insulin secretory defects in polycystic ovary syndrome. Relationship to insulin sensitivity and family history of noninsulin-dependent diabetes mellitus. J Clin Invest 1995;96:520–527.CrossRefPubMedGoogle Scholar
  46. 46.
    Holte J, Bergh T, Berne C, et al. Restored insulin sensitivity but persistently increased early insulin secretion after weight loss in obese women with polycystic ovary syndrome. J Clin Endocrinol Metab 1995;80:2586–2593.CrossRefPubMedGoogle Scholar
  47. 47.
    Gambineri A, Pelusi C, Manicardi E, et al. Glucose intolerance in a large cohort of mediterranean women with polycystic ovary syndrome: phenotype and associated factors. Diabetes 2004;53:2353–2358.CrossRefPubMedGoogle Scholar
  48. 48.
    Gennarelli G, Roveri R, Novi F, et al. Preserved insulin sensitivity and ß-cell activity, but decreased glucose effectiveness in normal weight women with polycystic ovary syndrome. J Clin Endocrinol Metab 2005;90:3381–3386.CrossRefPubMedGoogle Scholar
  49. 49.
    Holte J, Bergh Ch, Berglund L, Litthell H. Enhanced early phase insulin response to glucose in relation to insulin resistance in women with polycystic ovary syndrome. J Clin Endocrinol Metab 1994;78:1052–1058.CrossRefPubMedGoogle Scholar
  50. 50.
    Morin Papunen LC, Vahkonen I, Koivunen RM, Ruokonen A, Tapanainen JS. Insulin sensitivity, insulin secretion and metabolic and hormonal parameters in healthy women and women with polycystic ovary syndrome. Hum Reprod 2004;15:1266–1274.CrossRefGoogle Scholar
  51. 51.
    Vrbikova J, Cibula D, Dvorakova K, et al. Insulin sensitivity in women with polycystic ovary syndrome. J Clin Endocrinol Metab 2004;89:2942–2945.CrossRefPubMedGoogle Scholar
  52. 52.
    Wijeyartne CN, Balen AH, Barth JH, Belchetz PE. Clinical manifestation and insulin resistance (IR) in polycystic ovary syndrome (PCOS) among South Asians and Caucasians: is there a difference? Clin Endocrinol (Oxf) 2002;57:343–350.CrossRefGoogle Scholar
  53. 53.
    Matusda M, De Fronzo RA. Insulin sensitivity indices obtained from oral glucose tolerance testing. Diabetes Care 1999;22:1462–1470.CrossRefGoogle Scholar
  54. 54.
    Pasquali R, Patton L, Pagotto U, Gambineri A. Metabolic alterations and cardiovascular risk factors in the polycystic ovary syndrome. Min Ginecol 2005;57:79–85.Google Scholar
  55. 55.
    Pasquali R, Patton L, Pagotto U, Gambineri A. Metabolic alterations and cardiovascular risk factors in the polycystic ovary syndrome. Min Ginecol 2005;57:79–85.Google Scholar
  56. 56.
    Pasquali R, Gambineri A, Anconetani B, et al. The natural history of the metabolie syndrome in young women with the polycystic ovary syndrome and the long-term effect of oestrogen-progestagen treatment. Clin Endocrinol (Oxf) 1999;50:517–527.CrossRefGoogle Scholar
  57. 57.
    Legro RS, Gnatuk CL, Kunselman AR, Dunaif A. Changes in glucose tolerance over time in women with polycystic ovary syndrome: a controlled study. J Clin Endocrinol Metab 2005;90:3236–3242.CrossRefPubMedGoogle Scholar
  58. 58.
    Harris MI, Hadden WC, Knowler WC. Prevalence of diabetes and impaired glucose tolerance and plasma glucose levels in the US population aged 20–74. Diabetes 1987;36:523–534.CrossRefPubMedGoogle Scholar
  59. 59.
    Hofman PL, Cutfiled WS, Robinson EM, et al. Insulin resistance in short children with intrauterine growth retardation. J Clin Endocrinol Metab 1997;82:402–406.CrossRefPubMedGoogle Scholar
  60. 60.
    Phillips DI. Insulin resistance as a programmed response to fetal undernutrition. Diabetologia 1996;39:1119–1122.CrossRefPubMedGoogle Scholar
  61. 61.
    Glueck CJ, Papanna R, Wang P, Goldemberg N, Sieve-Smith L. Incidence and treatment of metabolic syndrome in newly referred women with confirmed polycystic ovarian syndrome. Metabolism 2003; 52:908–915.CrossRefPubMedGoogle Scholar
  62. 62.
    US Department of Health and Human Services (DHHS). National Center for Health Statistics. Third National Health and Nutrition Examination Survey, 1988–1994, NHANES III, 1996, Hyattsville, MD, Center for Disease Control and Prevention. Ref type: Data File.Google Scholar
  63. 63.
    Kohronen S, Hippelainen M, Vanhala M, Heinonen S, Niskanen L. The androgenic sex hormone profile is an essential feature of metabolic syndrome in premenopausal women: a controlled community-based study. Fertil Steril 2003;79:1327–1334.CrossRefGoogle Scholar
  64. 64.
    Legro RS, Kunselman AR, Dodson WC, Dunaif A. Prevalence and predictions of the risk of type 2 diabetes mellitus and impaired glucose tolerance in polycystic ovary syndrome: a prospective, controlled study in 254 affected women. J Clin Endocrinol Metab 1999;84:165–169.CrossRefPubMedGoogle Scholar
  65. 65.
    Ehrmann DA, Barnes RB, Rosenfield RL, Cavaghan MK, Imperial J. Prevalence of impaired glucose tolerance and diabetes in women with polycystic ovary syndrome. Diabetes Care 1999;22:141–146.CrossRefPubMedGoogle Scholar
  66. 66.
    Weerakiet S, Srisombut C, Bunnag P, Sangtong S, Chuangsoongnoen N, Rojanasakul A. Prevalence of type 2 diabetes mellitus and impaired glucose tolerance in Asian women with polycystic ovary syndrome. Int J Gynaecol Obstet 2001;75:177–184.CrossRefPubMedGoogle Scholar
  67. 67.
    Norris SL, Zhang X, Avenell A, et al. Long-term effectiveness of lifestyle and behavioral weight loss interventions in adults with type 2 diabetes: a meta-analysis. Am J Med 2004;117:762–774.CrossRefPubMedGoogle Scholar
  68. 68.
    Kanaya AM, Narayan KM. Prevention of type 2 diabetes: data from recent trials. Prim Care 2003;30:511–526.PubMedGoogle Scholar

Copyright information

© Humana Press Inc. 2007

Authors and Affiliations

  • Renato Pasquali
    • 1
  • Alessandra Gambineri
    • 1
  1. 1.Endocrinology Unit, Department of Internal Medicine and Gastroenterology and C.R.B.A., S. Orsola-Malpighi HospitalAlma Mater Studiorum University of BolognaBolognaItaly

Personalised recommendations